Vivus' EvaMist Gets FDA Approval Monday July 30, 8:41 am ET Licensee KV Pharmaceutical's Says Vivus' Menopause Drug EvaMist Approved in the U.S.
NEW YORK (AP) -- KV Pharmaceutical Co. and Vivus Inc. said Monday the Food and Drug Administration approved Vivus' EvaMist for symptoms associated with menopause. St. Louis-based KV Pharmaceutical licensed U.S. marketing rights to the drug from Mountain View, Calif.-based Vivus in March. Vivus is eligible to receive a $140 million cash payment upon approval of the drug. The deal also calls for two separate milestone payments of up to $30 million. Those payments are based on annual sales levels.
EvaMist is expected to be launched during the second half of KV Pharmaceutical's fiscal year 2008.
ACR Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
